Enanta Pharmaceuticals vs Fortress Biotech
ENTA and FBIO side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ENTA and FBIO compare
Enanta Pharmaceuticals is the larger company, worth 4.6 times as much as Fortress Biotech ($338M against $73.9M).
Fortress Biotech keeps more of each dollar of sales as profit, with a net margin of 163% compared with −96.9% at Enanta Pharmaceuticals.
Fortress Biotech scores higher on the StockData Score (9 against 2 for Enanta Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ENTA | FBIO |
|---|---|---|
| Size and price | ||
| Market cap | $338M | $73.9M |
| Share price | $11.60 | $2.01 |
| Change, 1 year | 0.78% | −22.4% |
| Change, 5 years | −84.6% | −95.7% |
| Beta (5Y) | 1.15 | 1.38 |
| Employees | 120 | 78 |
| StockData Score | ||
| Total score | 2 | 9 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 3 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.2× | 1.1× (better) |
| P/B | 3.3× | 0.5× (better) |
| FCF yield | −10.9% | – |
| Fair value | $9.56 | – |
| Margin of safety | −21.4% | – |
| Growth | ||
| Revenue growth (TTM) | – | 15.5% |
| Revenue growth, 5Y average | −11.8% | 6.8% (better) |
| Profitability | ||
| Gross margin | – | 65.6% |
| Operating margin | −90.0% | −42.9% (better) |
| Net margin | −96.9% | 163% (better) |
| FCF margin | −56.6% | – |
| Return on equity | −70.1% | 107% (better) |
| Return on invested capital | – | −261% |
| Financial health | ||
| Debt / equity | – | 0.21 |
| Interest coverage | −4.5× | −3.0× (better) |
| Current ratio | 3.76 | 3.96 (better) |
| Altman Z-score | −0.91 (better) | −1.75 |
| Piotroski F-score | 4 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 93.6% | 15.9% |
| Held by insiders | 7.9% | 31.6% |
| Insider net buying, 12 months | −$183K | – |
| Short interest, % of float | 6.9% | – |
Go deeper
- ENTA stock overview
- ENTA income statement
- ENTA valuation and score
- FBIO stock overview
- FBIO income statement
- FBIO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.